Latest News Archive

Please select Category, Year, and then Month to display items

The first clinical PhD in nuclear medicine completed at the UFS

18 April 2024 | Story Andre Damons | Photo Charl Devenish

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans.

News Archive

Chemistry gets substantial grants

2013-06-10

At the experimental setup of the high temperature reduction oven for research in heterogeneous catalysis are, front from left: Maretha Serdyn (MNS Cluster prestige PhD bursar), Nceba Magqi (Sasol employee busy with his MSc in Chemistry) and Dr Alice Brink (Formal MNS Cluster postdoctoral fellow and lecturer in Inorganic Chemistry); back Profs Jannie Swarts (Head: Physical Chemistry), André Roodt, and Ben Bezuidenhoudt (Sasol Professor in Organic and Process Chemistry).
10 June 2013

Three research groups in the Department of Chemistry received substantial grants to the value of R4,55 million. The funding includes bursaries for students and post-doctoral fellows, mobility grants, running costs and equipment support, as well as dedicated funds for two young scientists in the UFS Prestige Scholar Programme, Drs Lizette Erasmus and Alice Brink.

The funding comes from Sasol, the THRIP programme of the National Research Foundation (NRF) and PetLabs Pharmaceuticals for the overarching thrust in Organic Synthesis, Homogeneous and Heterogeneous Catalysis. The programme has a broad focuse on different fundamental and applied aspects of process chemistry. Research groups of Profs Andreas Roodt (Inorganic), Jannie Swarts (Physical) and Ben Bezuidenhoudt (Organic / Process), principal members of the focus area of (Green) Petrochemicals in the Materials and Nanosciences Strategic Research Cluster (MNS Cluster) will benefit from the grant.

This funding was granted based on the continued and high-level outputs by the groups, which resulted in more than 40 papers featuring in international chemistry publications in merely the past year. A few papers also appeared in the top experimental inorganic chemistry journal from the American Chemical Society, Inorganic Chemistry. These high-impact papers address important issues in catalysis under the UFS Material and Nanosciences Research Cluster initiative, as well as other aspects of fundamental chemistry, but with an applied approach and focus.

Prof Andreas Roodt, Distinguished Professor and Chairperson of the Department of Chemistry, said the grants will enable the three research groups to move forward in their respective research areas associated with petrochemicals and other projects, and enable additional students in the department to benefit from it. It will also ensure that these groups can continue and maintain their research on different molecular and nano-scale materials. Current experiments include conversions under extremely high gas pressures (typical 100 times that in motor car tyres). This takes place at the molecular level and at preselected nano-surfaces, to convert cheaper feed-stream starting materials into higher value-added products for use as special additives in gasoline and other speciality chemicals.

The funding support forms part of the Hub-and-Spoke initiative at Sasol under which certain universities and specifically the UFS Department of Chemistry have been identified for strategic support for research and development. The department and the UFS gratefully acknowledge this continued and generous support from all parties concerned.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept